Bayer's Expert Mondays 2024 in collaboration with Inpart Connect
Knowledge Sharing for Innovators | Meet & Greet with Bayer Scouts & Scientific Finders
11 a.m. ET | 5 p.m. CET on select Mondays, February - December 2024
For more information on sessions, see below
Calling pre-seed and seed innovators and entrepreneurs in Oncology, Cell & Gene Therapy, Cardiovascular, Immunology, Radiology, and Digital Health!
Do you have disruptive science but struggle to bring it to life in the entrepreneurial world? Bayer's passion is to enable and support standout healthcare innovation!
Take your innovation to new heights and join Bayer´s Expert Mondays 2024, a series of knowledge exchange sessions to supercharge your start-up’s growth.
In 2023, Bayer's Expert Mondays brought together over 2,500 innovators across 13 sessions. Let's build on this success and continue Collaborating to Cure to bring breakthrough innovation to patients.
What you need to know
- Each one-hour Bayer's Expert Monday includes a live Q&A with respective Bayer Experts.
- You can stay for a Meet & Greet with Bayer Scouts & Scientific Finders. Please reserve 30 additional minutes in your schedule for the Meet & Greet after the Bayer Expert session.
- These sessions are not intended for service providers, consultants, IT providers, etc. They are designed for drug developers and healthcare researchers seeking collaboration with big pharma and out-licensing opportunities later in their journey.
- Session recordings are NOT distributed afterward. Live attendance is necessary to get the most out of the expert sessions and network with the Bayer Pharma team.
- Each session has a maximum capacity of 500 participants.
|
Theme |
Date |
|
Experts |
|
Grow Your Innovation & Get it to Market |
26 Feb |
Clinical Operations in 2050 |
Dr. Bernhard Glombitza VP, Head of Clinical OPS EMEA & APAC |
|
11 March |
EU Legislative Impact on Emerging European Innovation |
Dr. Daniel Steiners SVP, General Manager Bayer Pharma Germany
Edouard Ohleyer Access & Value Policy Lead, Global Pharma Public Affairs |
|
|
22 April |
Cell & Gene Market Access Planning Differences in EMEA & US |
Dr. Markus Frick Global Market Access Lead, Cell & Gene |
|
|
13 May |
Cell & Gene Regulatory Jungle in the EU & US |
Dr. Isabelle Stoeckert VP, Head RA EMEA
Dr. Gabriele Bräunlich VP, RA EMEA, Head RA Strategy
Dr. Jana Napolitano RA Strategy, New Modalities |
|
|
Prepare for Dealmaking |
15 April |
Global Deal Trends, incl. Cell & Gene deals |
Yan Jiang, PhD Sr. Dir. BD&L, BD Insights |
|
24 June |
How does Big Pharma Evaluate Partnering Offers? + Tips on Preparing Non-Conf. Pitch Decks |
Sebastian Karrer Head of BD&L EMEA CtC Hub EMEA
Tanja Bloser Ecosystem Activation, CtC Hub EMEA |
|
|
Collaboration Incubation Manufacturing |
26 Aug |
Co.Lab Global Incubators & Cell & Gene Translational Center Berlin |
Dr. JP Kruse Senior Director BD&L, Co.Lab Berlin
Dr. Daniel Forler Senior Director BD&L |
|
30 Sept |
Demystify Due Diligence with Big Pharma |
Dr. Anja Moews & Senior Directors BD&L, Due Diligence Center of Excellence |
|
|
18 Nov |
Overcome Challenges & Risks in Cell & Gene Manufacturing/CMC Development |
Dr. Jens Vogel SVP, Global Head of Biotech |
|
|
2 Dec |
Bayer´s Collaboration Models & Alliance Management |
Dr. Hanna Eilken & Dr. Christoph Huwe Senior Directors BD&L, Alliance Management |
|
|
9 Dec |
Ingredients to Successful Partnerships: Big Pharma + Biotech/Start-ups |
Nicolas Becker & Jeremy Booth Senior Directors BD&L, Alliance Management |
